Next Article in Journal
Accrual of Adolescents and Young Adults with Cancer to Clinical Trials
Previous Article in Journal
Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 2
10.3747/co.23.2955
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Response to: Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?

by
Ma Kim Anh
1,2,*,
Goulnar Kasymjanova
2,
Victor Cohen
2 and
Jason Agulnik
2
1
Division of Hematology/Oncology, McGill University, Montreal, QC, Canada
2
Peter Brojde Lung Cancer Centre, Jewish General Hospital, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(2), 160-161; https://doi.org/10.3747/co.23.2955
Submission received: 12 January 2016 / Revised: 11 February 2016 / Accepted: 11 March 2016 / Published: 1 April 2016

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We thank Drs. Ibrahim Elghissassi, Saber Boutayeb, Hanane Inrhaoun, Hind Mrabti, and Hassan Errihani for their comments on our paper [...]

Share and Cite

MDPI and ACS Style

Anh, M.K.; Kasymjanova, G.; Cohen, V.; Agulnik, J. Response to: Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach? Curr. Oncol. 2016, 23, 160-161. https://doi.org/10.3747/co.23.2955

AMA Style

Anh MK, Kasymjanova G, Cohen V, Agulnik J. Response to: Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach? Current Oncology. 2016; 23(2):160-161. https://doi.org/10.3747/co.23.2955

Chicago/Turabian Style

Anh, Ma Kim, Goulnar Kasymjanova, Victor Cohen, and Jason Agulnik. 2016. "Response to: Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?" Current Oncology 23, no. 2: 160-161. https://doi.org/10.3747/co.23.2955

APA Style

Anh, M. K., Kasymjanova, G., Cohen, V., & Agulnik, J. (2016). Response to: Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach? Current Oncology, 23(2), 160-161. https://doi.org/10.3747/co.23.2955

Article Metrics

Back to TopTop